Similar articles for PMID: 28385901

Year	Number of Results
1991	1
2001	1
2003	2
2004	2
2005	1
2006	2
2007	1
2008	3
2009	2
2010	1
2011	3
2012	2
2013	3
2014	4
2015	9
2016	1
2017	1
2024	0

1

Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.

[No authors listed] [No authors listed] CMAJ. 2017 Apr 3;189(13):E511. doi: 10.1503/cmaj.170248. CMAJ. 2017. PMID: 28385901 Free PMC article. No abstract available.

2

Availability of medicines in public sector health facilities of two North Indian States.

Prinja S, Bahuguna P, Tripathy JP, Kumar R. Prinja S, et al. BMC Pharmacol Toxicol. 2015 Dec 23;16:43. doi: 10.1186/s40360-015-0043-8. BMC Pharmacol Toxicol. 2015. PMID: 26699711 Free PMC article.

3

Here today, gone tomorrow: the issue attention cycle and national print media coverage of prescription drug financing in Canada.

Daw JR, Morgan SG, Thomson PA, Law MR. Daw JR, et al. Health Policy. 2013 Apr;110(1):67-75. doi: 10.1016/j.healthpol.2013.01.006. Epub 2013 Feb 16. Health Policy. 2013. PMID: 23419420

4

Drug coverage in Canada: who is at risk?

Kapur V, Basu K. Kapur V, et al. Health Policy. 2005 Feb;71(2):181-93. doi: 10.1016/j.healthpol.2004.08.006. Health Policy. 2005. PMID: 15607380

5

The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.

Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. Teerawattananon Y, et al. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404. doi: 10.1016/j.zefq.2014.06.017. Epub 2014 Aug 23. Z Evid Fortbild Qual Gesundhwes. 2014. PMID: 25444298

6

Universal access to medicines: evidence from Rajasthan, India.

Selvaraj S, Mukhopadhyay I, Kumar P, Aisola M, Datta P, Bhat P, Mehta A, Srivastava S, Pachauli C. Selvaraj S, et al. WHO South East Asia J Public Health. 2014 Jul-Dec;3(3):289-299. doi: 10.4103/2224-3151.206752. WHO South East Asia J Public Health. 2014. PMID: 28612814

7

Framing incremental expansions to public health insurance systems: the case of Canadian pharmacare.

Daw JR, Morgan SG, Collins PA, Abelson J. Daw JR, et al. J Health Polit Policy Law. 2014 Apr;39(2):295-330. doi: 10.1215/03616878-2416229. J Health Polit Policy Law. 2014. PMID: 24711215

8

How to anticipate the assessment of the public health benefit of new medicines?

Massol J, Puech A, Boissel JP; Participants inRound Table No 7, Giens XXII. Massol J, et al. Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071. Epub 2008 Jan 19. Therapie. 2007. PMID: 18206104

9

Access to essential medicines for sexual and reproductive health care: the role of the pharmaceutical industry and international regulation.

Cottingham J, Berer M. Cottingham J, et al. Reprod Health Matters. 2011 Nov;19(38):69-84. doi: 10.1016/S0968-8080(11)38573-4. Reprod Health Matters. 2011. PMID: 22118143

10

An American approach to health system reform.

Holahan J, Moon M, Welch WP, Zuckerman S. Holahan J, et al. JAMA. 1991 May 15;265(19):2537-40. JAMA. 1991. PMID: 2020072

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

37 results

Results by year